A skewed ratio of free light chains is more common in patients with late-onset than early-onset myasthenia gravis
Immunology Letters · 2023
DOI: 10.1016/j.imlet.2023.07.001 ↗Kurz gefasst
Fachartikel in der Zeitschrift Immunology Letters, 2023. Verfasst von Chris Myllynen und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosciences, University of Helsinki, Helsinki, Finland. Electronic address: chris.myllynen@helsinki.fi. Hauptthemen laut MEDLINE: Proteomics, Myasthenia Gravis. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: HUS Helsinki University Hospital.
Abstract (Originalsprache)
Myasthenia gravis (MG) is an autoantibody-mediated neuromuscular disease with an unpredictable clinical course. Serum free light chains (FLCs) have risen as a promising biomarker for MG, but their role in different subtypes of MG and in predicting disease progression is still uncharted. We investigated plasma from 58 generalized MG patients during post-thymectomy follow-up to determine κ and λ FLC and κ/λ ratio. In a subcohort of 30 patients, we examined the expression of 92 proteins associated with immuno-oncology using Olink. We further studied the ability of FLCs or proteomic markers to differentiate disease severity. Patients with late-onset MG (LOMG) displayed significantly higher mean κ/λ ratio than patients with early-onset MG (P = 0.004). Inducible T-cell co-stimulator ligand (ICOSLG), matrix metalloproteinase 7 (MMP7), hepatocyte growth factor (HGF), and arginase 1 (ARG1) were differentially expressed in MG patients compared to healthy controls. There were no significant associations between clinical outcomes and FLCs or the assayed proteins. In conclusion, an elevated κ/λ ratio suggests long-lasting aberrant clonal plasma cell function in LOMG. Immuno-oncology-related proteomic analysis showed alterations in immunoregulatory pathways. Our findings pinpoint the FLC ratio as a biomarker for LOMG and call for further investigation of the immunoregulatory pathways in MG.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurosciences, University of Helsinki, Helsinki, Finland. Electronic address: chris.myllynen@helsinki.fi.
- Translational Immunology Research Program, University of Helsinki, Helsinki, Finland.
- Department of Neurosciences, University of Helsinki, Helsinki, Finland; Department of Neurology, Neurocenter, Helsinki University Hospital, Helsinki, Finland.
- Translational Immunology Research Program, University of Helsinki, Helsinki, Finland; Department of Neurology, Neurocenter, Helsinki University Hospital, Helsinki, Finland.
- Translational Immunology Research Program, University of Helsinki, Helsinki, Finland; HUS Diagnostic Center, HUSLAB Clinical Microbiology, Helsinki University Hospital, Helsinki, Finland.
- Department of Neurosciences, University of Helsinki, Helsinki, Finland; Translational Immunology Research Program, University of Helsinki, Helsinki, Finland; Department of Neurology, Neurocenter, Helsinki University Hos…
Förderung
- HUS Helsinki University Hospital
Zitieren
APA
Myllynen, C., Sarkkinen, J., Atula, S., Tienari, P., Kekäläinen, E., & Laakso, S. M. (2023). A skewed ratio of free light chains is more common in patients with late-onset than early-onset myasthenia gravis. Immunology Letters. https://doi.org/10.1016/j.imlet.2023.07.001
Vancouver
Myllynen C, Sarkkinen J, Atula S, Tienari P, Kekäläinen E, Laakso SM. A skewed ratio of free light chains is more common in patients with late-onset than early-onset myasthenia gravis. Immunology Letters. 2023. doi:10.1016/j.imlet.2023.07.001
BibTeX
@article{Myllynen2023,
author = {Myllynen, Chris and Sarkkinen, Joona and Atula, Sari and Tienari, Pentti and Kekäläinen, Eliisa and Laakso, Sini M},
title = {A skewed ratio of free light chains is more common in patients with late-onset than early-onset myasthenia gravis},
journal = {Immunology Letters},
year = {2023},
doi = {10.1016/j.imlet.2023.07.001}
}
EUVIMED